# Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy

> **NCT01353469** · PHASE3 · COMPLETED · sponsor: **Sanofi** · enrollment: 485 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus

## Interventions

- **DRUG:** Insulin human/Insuman Comb 25 (HR1799)
- **DRUG:** Insulin human/Novolin® 30R

## Key facts

- **NCT ID:** NCT01353469
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 485 (ACTUAL)
- **Last updated:** 2013-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01353469

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01353469, "Assessment of Efficacy and Safety of Insuman Comb 25 Versus Novolin® 30R Twice Daily Over 24 Weeks in Type 2 Diabetes Patients With Insulin Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT01353469. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*